Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages

被引:83
作者
Williams, Lynn M. [1 ]
Sarma, Usha [1 ]
Willets, Kate [1 ]
Smallie, Tim [1 ]
Brennan, Fionula [1 ]
Foxwell, Brian M. J. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol Div, London W6 8LH, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
D O I
10.1074/jbc.M609101200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is general agreement that signal transducer and activation of transcription 3 (STAT3) is required to mediate the antiinflammatory activities of interleukin (IL)-10. However, STAT3 is activated by multiple factors that do not share the anti-inflammatory activity of IL-10. The question remains whether STAT3 is sufficient for the anti-inflammatory effects or whether there are other signals required, as had been suggested previously. We set out to map the human IL-10 receptor and to identify the key elements involved in transducing the cytokine-suppressive effects of IL-10. We were able to show an absolute requirement for both of the tyrosine residues found within the YXXQ-STAT3-docking site within the IL-10 receptor I and that no other signals appeared to be required. We used a constitutively active STAT3 to determine whether expression of this factor could suppress lipopolysaccharide-induced tumor necrosis factor and IL-6 production. Our data show that STAT3 activity can suppress both IL-6 and tumor necrosis factor production in lipopolysaccharide-stimulated macrophages. However, in synovial fibroblasts, STAT3 did not suppress IL-6 production, suggesting that the cellular environment plays an important role in dictating whether STAT3 drives a pro- or anti-inflammatory response.
引用
收藏
页码:6965 / 6975
页数:11
相关论文
共 62 条
[1]   Heterogeneous requirement of IκB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis -: Implications for therapy [J].
Andreakos, E ;
Smith, C ;
Kiriakidis, S ;
Monaco, C ;
de Martin, R ;
Brennan, FM ;
Paleolog, E ;
Feldmann, M ;
Foxwell, BM .
ARTHRITIS AND RHEUMATISM, 2003, 48 (07) :1901-1912
[2]  
Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936
[3]  
Besser D, 1999, MOL CELL BIOL, V19, P1401
[4]   Regulation of chemokine mRNA stability by lipopolysaccharide and IL-10 [J].
Biswas, R ;
Datta, S ;
Das Gupta, J ;
Novotny, M ;
Tebo, J ;
Hamilton, TA .
JOURNAL OF IMMUNOLOGY, 2003, 170 (12) :6202-6208
[5]  
BOGDAN C, 1992, J BIOL CHEM, V267, P23301
[6]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[7]   INTERLEUKIN-10 DIFFERENTIALLY REGULATES B7-1 (CD80) AND B7-2 (CD86) EXPRESSION ON HUMAN PERIPHERAL-BLOOD DENDRITIC CELLS [J].
BUELENS, C ;
WILLEMS, F ;
DELVAUX, A ;
PIERARD, G ;
DELVILLE, JP ;
VELU, T ;
GOLDMAN, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (09) :2668-2672
[8]   B7-1 EXPRESSION OF LANGERHANS CELLS IS UP-REGULATED BY PROINFLAMMATORY CYTOKINES, AND IS DOWN-REGULATED BY INTERFERON-GAMMA OR BY INTERLEUKIN-10 [J].
CHANG, CH ;
FURUE, M ;
TAMAKI, K .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (02) :394-398
[9]  
Clarke CJP, 1998, EUR J IMMUNOL, V28, P1719, DOI 10.1002/(SICI)1521-4141(199805)28:05<1719::AID-IMMU1719>3.0.CO
[10]  
2-Q